Glizamide M 60-1000 Tablet contains Gliclazide 60 mg and Metformin 1000 mg, a synergistic dual antidiabetic combination designed to achieve comprehensive glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea, enhances insulin secretion from pancreatic beta cells, while Metformin improves peripheral insulin sensitivity and reduces hepatic glucose production.
Clinically, this combination is indicated for patients with inadequately controlled type 2 diabetes on monotherapy, particularly where insulin resistance and impaired insulin secretion coexist. The higher Metformin strength supports robust fasting and postprandial glucose control, while modified-release Gliclazide helps maintain stable blood glucose levels.
The tablet formulation ensures precise dosing, consistent bioavailability, and predictable therapeutic outcomes, making it suitable for diabetes clinics, hospitals, endocrinology practices, and long-term outpatient management. Oral administration promotes ease of use and improved patient adherence in chronic diabetes care.
Glizamide M 60-1000 Tablet helps in reducing HbA1c levels, stabilizing daily glucose fluctuations, and lowering the risk of diabetes-related complications. Its well-established efficacy and safety profile make it a preferred combination therapy for sustained glycemic management under medical supervision.